Amgen, Inc. vs YieldMax COIN Option Income Strategy ETF — how do they compare? Amgen, Inc. trades at $412.77 (market cap $224.14B), while YieldMax COIN Option Income Strategy ETF trades at $18.12. The key difference: Amgen, Inc. pays a 2.43% dividend while YieldMax COIN Option Income Strategy ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | CONY | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $417.20 | $76.50 |
52-Week Low | $271.18 | $17.80 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →